| Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations AR Padhani, G Liu, D Mu-Koh, TL Chenevert, HC Thoeny, T Takahara, ... Neoplasia 11 (2), 102-125, 2009 | 2345 | 2009 |
| Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... New England Journal of Medicine 366 (15), 1382-1392, 2012 | 2084 | 2012 |
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised … J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 15 (8), 852-861, 2014 | 1703 | 2014 |
| Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) AK Kakkar, MN Levine, Z Kadziola, NR Lemoine, V Low, HK Patel, ... Journal of Clinical Oncology 22 (10), 1944-1948, 2004 | 893 | 2004 |
| Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ... The Lancet Oncology 16 (8), 928-936, 2015 | 883 | 2015 |
| Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial GJS Rustin, MEL Van Der Burg, CL Griffin, D Guthrie, A Lamont, ... The Lancet 376 (9747), 1155-1163, 2010 | 734 | 2010 |
| Phase i trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) ES Newlands, GRP Blackledge, JA Slack, GJ Rustin, DB Smith, NS Stuart, ... British journal of cancer 65 (2), 287-291, 1992 | 637 | 1992 |
| Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG) GJS Rustin, I Vergote, E Eisenhauer, E Pujade-Lauraine, M Quinn, ... International Journal of Gynecologic Cancer 21 (2), 2011 | 610 | 2011 |
| Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial RTD Oliver, MD Mason, GM Mead, H von der Maase, GJS Rustin, JK Joffe, ... The Lancet 366 (9482), 293-300, 2005 | 587* | 2005 |
| The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations MO Leach, KM Brindle, JL Evelhoch, JR Griffiths, MR Horsman, A Jackson, ... British journal of cancer 92 (9), 1599-1610, 2005 | 583 | 2005 |
| 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG … A Du Bois, M Quinn, T Thigpen, J Vermorken, E Avall-Lundqvist, ... Annals of oncology 16, viii7-viii12, 2005 | 545 | 2005 |
| Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo … JA Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 17 (11), 1579-1589, 2016 | 489 | 2016 |
| Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. GJ Rustin, AE Nelstrop, P McClean, MF Brady, WP McGuire, WJ Hoskins, ... Journal of Clinical Oncology 14 (5), 1545-1551, 1996 | 449 | 1996 |
| Role of tumour markers in monitoring epithelial ovarian cancer T Meyer, GJS Rustin British journal of cancer 82 (9), 1535-1538, 2000 | 440 | 2000 |
| CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use MJ DUFFY, JM BONFRER, J Kulpa, GJS Rustin, G Soletormos, GC Torre, ... International Journal of Gynecologic Cancer 15 (5), 2005 | 420 | 2005 |
| Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study GJS Rustin, AE Nelstrop, MK Tuxen, HE Lambert Annals of oncology 7 (4), 361-364, 1996 | 408 | 1996 |
| Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis SM Galbraith, MA Lodge, NJ Taylor, GJS Rustin, S Bentzen, JJ Stirling, ... NMR in Biomedicine: An International Journal Devoted to the Development and …, 2002 | 401 | 2002 |
| Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging SM Galbraith, RJ Maxwell, MA Lodge, GM Tozer, J Wilson, NJ Taylor, ... Journal of clinical oncology 21 (15), 2831-2842, 2003 | 390 | 2003 |
| EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. M Bower, ES Newlands, L Holden, D Short, C Brock, GJ Rustin, ... Journal of Clinical Oncology 15 (7), 2636-2643, 1997 | 386 | 1997 |
| Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results GJS Rustin, SM Galbraith, H Anderson, M Stratford, LK Folkes, L Sena, ... Journal of clinical oncology 21 (15), 2815-2822, 2003 | 384 | 2003 |
